REVELATION BIOSCIENCES INC (REVB) Stock Price & Overview

NASDAQ:REVB • US76135L8046

Current stock price

1.25 USD
+0.02 (+1.63%)
At close:
1.21 USD
-0.04 (-3.2%)
After Hours:

The current stock price of REVB is 1.25 USD. Today REVB is up by 1.63%. In the past month the price increased by 0.81%. In the past year, price decreased by -96.11%.

REVB Key Statistics

52-Week Range1.06 - 44.7696
Current REVB stock price positioned within its 52-week range.
1-Month Range1.06 - 1.4276
Current REVB stock price positioned within its 1-month range.
Market Cap
4.65M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-84.39
Dividend Yield
N/A

REVB Stock Performance

Today
+1.63%
1 Week
+10.62%
1 Month
+0.81%
3 Months
-61.57%
Longer-term
6 Months -79.17%
1 Year -96.11%
2 Years -99.69%
3 Years -99.98%
5 Years N/A
10 Years N/A

REVB Stock Chart

REVELATION BIOSCIENCES INC / REVB Daily stock chart

REVB Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to REVB. When comparing the yearly performance of all stocks, REVB is a bad performer in the overall market: 98.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

REVB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to REVB. REVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

REVB Earnings

Next Earnings DateMay 6, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$23.95
Revenue Reported
EPS Surprise -541.54%
Revenue Surprise %

REVB Forecast & Estimates

7 analysts have analysed REVB and the average price target is 54.06 USD. This implies a price increase of 4224.8% is expected in the next year compared to the current price of 1.25.


Analysts
Analysts82.86
Price Target54.06 (4224.8%)
EPS Next Y94.98%
Revenue Next YearN/A

REVB Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

REVB Financial Highlights

Over the last trailing twelve months REVB reported a non-GAAP Earnings per Share(EPS) of -84.39. The EPS increased by 94.97% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-14.87M
Industry RankSector Rank
PM (TTM) N/A
ROA -128.34%
ROE -167.76%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%59.92%
Sales Q2Q%N/A
EPS 1Y (TTM)94.97%
Revenue 1Y (TTM)N/A

REVB Ownership

Ownership
Inst Owners8.27%
Shares3.72M
Float3.51M
Ins Owners2.13%
Short Float %0.75%
Short Ratio0.01

About REVB

Company Profile

REVB logo image Revelation Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Company Info

IPO: 2020-10-08

REVELATION BIOSCIENCES INC

4660 Lajolla Village Drive, Suite 100

San Diego CALIFORNIA US

Employees: 8

REVB Company Website

REVB Investor Relations

Phone: 13026457400

REVELATION BIOSCIENCES INC / REVB FAQ

Can you describe the business of REVELATION BIOSCIENCES INC?

Revelation Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. Revelation Biosciences, Inc. is a clinical-stage life sciences company, which is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.


What is the current price of REVB stock?

The current stock price of REVB is 1.25 USD. The price increased by 1.63% in the last trading session.


Does REVELATION BIOSCIENCES INC pay dividends?

REVB does not pay a dividend.


What is the ChartMill technical and fundamental rating of REVB stock?

REVB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for REVELATION BIOSCIENCES INC?

REVELATION BIOSCIENCES INC (REVB) operates in the Health Care sector and the Biotechnology industry.


What is REVELATION BIOSCIENCES INC worth?

REVELATION BIOSCIENCES INC (REVB) has a market capitalization of 4.65M USD. This makes REVB a Nano Cap stock.


What is the outstanding short interest for REVELATION BIOSCIENCES INC?

The outstanding short interest for REVELATION BIOSCIENCES INC (REVB) is 0.75% of its float.